Jackson Financial heads into September having quietly done something unusual: gained ground while almost everything around it fell apart.
The stock closed Tuesday at $132.78, up nearly 1% on the week. That modest gain looks better in context. Close peers EQH and CRBG each added around 1% — broadly in line — but further out in the peer group the damage was real. PYPL dropped 15.9% on the week. CHYM fell 4.4%. APO shed 1.1%. JXN's 8.6% gain over the past month now looks like a genuine divergence, not noise.
The lending market adds little drama here, and that's part of the story. Short interest is a modest 4.9% of free float — down 15% from a month ago — as shorts have been quietly unwinding through August. Availability is extraordinarily loose at 4,464%, meaning there are roughly 44 shares available to borrow for every one currently on loan. Cost to borrow has ticked up 17% on the week but remains negligible at 0.44% annually, well within the "easy borrow" category. Options positioning is structurally elevated — the put/call ratio runs at 3.41, near its 20-day average of 3.32 — but this appears structural for the name rather than a fresh defensive signal; the z-score is just 0.34, barely a whisper above normal. Taken together, there is no meaningful squeeze pressure and no surge in hedging demand. Positioning looks comfortable rather than charged.
The Street has been steadily ratcheting targets higher following August's earnings beat. Barclays lifted its Overweight target to $149 from $139. Keefe, Bruyette & Woods raised to $140 from $130, staying at Market Perform. Evercore ISI moved to $135 from $128, also holding its In-Line rating. The consensus mean is $146, roughly 10% above the current price. Jefferies upgraded to Buy in early July, lifting its target to $140. The direction of travel from the analyst community is uniformly upward on price targets, even where conviction ratings haven't moved. Factor scores support the bull case: EPS momentum ranks in the 97th percentile on a 30-day basis and the 94th on 90 days. EPS surprise ranks in the 90th percentile. The short score of 43 is relatively benign, ranking in the 32nd percentile — meaning the data signals less short pressure than most names in the universe.
On the institutional register, BlackRock recently added shares, bringing its stake to 10% of the company. Dimensional Fund Advisors and Geode Capital Management also added modestly. TPG holds nearly 7% as a passive holder per its 13G filing, with no change in shares reported. Goldman Sachs trimmed by 381,000 shares as of June 30 — worth noting, though the position at 1.58% remains relatively small. No 13D activists are on the register. As a disclosure caveat: 13D/G stakes are event-driven around the 5% threshold, and holders dropping below that level may not file again.
Earnings history adds a useful calibration point. The two most recent prints produced outsized moves: the stock jumped 9.3% on the day of the August 2026 Q2 release, and gained another 6.6% five days later. The prior quarter saw a modest 0.2% decline on the day but a 2.2% drift lower over the following week. The next event is scheduled for November 4. Between now and then, the question worth tracking is whether the gap between the current price and the analyst consensus target at $146 narrows through further price appreciation or through a reset in Street expectations ahead of Q3 results.
See the live data behind this article on ORTEX.
Open JXN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
